

# L Lee Dupuis Rph

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6079997/publications.pdf>

Version: 2024-02-01

160  
papers

5,557  
citations

87888

38  
h-index

98798

67  
g-index

163  
all docs

163  
docs citations

163  
times ranked

5350  
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptom Screening in Pediatrics Tool in children and adolescents with high-risk malignancies: a pilot study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e70-e73.	1.6	3
2	Describing taste changes and their potential impacts on paediatric patients receiving cancer treatments. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e382-e388.	1.6	3
3	Finalising the administration of co-SSPedi, a dyad approach to symptom screening for paediatric patients receiving cancer treatments. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e469-e475.	1.6	5
4	Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e646-e649.	1.6	3
5	Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy. <i>Hispanic Health Care International</i> , 2022, 20, 33-39.	0.9	2
6	Perceptions of parents of pediatric patients with acute lymphoblastic leukemia on oral chemotherapy administration: A qualitative analysis. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29329.	1.5	8
7	<i>Clostridioides difficile</i> infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. <i>European Journal of Cancer</i> , 2022, 171, 1-9.	2.8	7
8	Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments. <i>BMC Cancer</i> , 2022, 22, .	2.6	5
9	Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF <sup>®</sup> in glass and plastic bottles and plastic syringes. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 78-87.	0.9	2
10	Feeling scared or worried self-report in children receiving cancer treatments using the Symptom Screening in Pediatrics Tool (SSPedi). <i>Supportive Care in Cancer</i> , 2021, 29, 3137-3144.	2.2	3
11	Reasons for disagreement between proxy-report and self-report rating of symptoms in children receiving cancer therapies. <i>Supportive Care in Cancer</i> , 2021, 29, 4165-4170.	2.2	10
12	Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28947.	1.5	13
13	Identifying clinical practice guidelines for symptom control in pediatric oncology. <i>Supportive Care in Cancer</i> , 2021, 29, 7049-7055.	2.2	8
14	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	7.1	14
15	Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study. <i>Implementation Science Communications</i> , 2021, 2, 106.	2.2	7
16	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 657-663.	2.0	7
17	Barriers to symptom management care pathway implementation in pediatric Cancer. <i>BMC Health Services Research</i> , 2021, 21, 1068.	2.2	6
18	Veno-occlusive disease after high-dose busulfan+melfalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study. <i>Supportive Care in Cancer</i> , 2020, 28, 933-938.	2.2	5
20	Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28044.	1.5	3
21	Feasibility of a randomized controlled trial of symptom screening and feedback to healthcare providers compared with standard of care using the SPARK platform. <i>Supportive Care in Cancer</i> , 2020, 28, 2729-2734.	2.2	7
22	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 226-236.	5.8	84
23	Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 141-150.	5.6	65
24	Development of the SPARK family member web pages to improve symptom management for pediatric patients receiving cancer treatments. <i>BMC Cancer</i> , 2020, 20, 923.	2.6	2
25	Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28716.	1.5	8
26	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	1.6	201
27	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
28	Conventional compared to network meta-analysis to evaluate antibiotic prophylaxis in patients with cancer and haematopoietic stem cell transplantation recipients. <i>BMJ Evidence-Based Medicine</i> , 2020, 26, bmjebm-2020-111362.	3.5	1
29	Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 2499-2509.	1.6	12
30	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
31	Discordance between pediatric self-report and parent proxy-report symptom scores and creation of a dyad symptom screening tool (coâ€SSPedi). <i>Cancer Medicine</i> , 2020, 9, 5526-5534.	2.8	15
32	Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. <i>Supportive Care in Cancer</i> , 2020, 28, 4761-4769.	2.2	15
33	Lexicon for guidance terminology in pediatric hematology/oncology: A White Paper. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28170.	1.5	7
34	Changes in hunger among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 5795-5801.	2.2	3
35	Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline. <i>European Journal of Cancer</i> , 2020, 131, 53-67.	2.8	33
36	Changes in taste among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. <i>Quality of Life Research</i> , 2019, 28, 2941-2949.	3.1	14

#	ARTICLE	IF	CITATIONS
37	Optimizing symptom control in children and adolescents with cancer. <i>Pediatric Research</i> , 2019, 86, 573-578.	2.3	27
38	Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. <i>Cancer Medicine</i> , 2019, 8, 4536-4546.	2.8	52
39	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
40	L'optimisation des médicaments à usage pédiatrique : une prescription pour les enfants et les adolescents canadiens. <i>Paediatrics and Child Health</i> , 2019, 24, 336-339.	0.6	0
41	Improving paediatric medications: A prescription for Canadian children and youth. <i>Paediatrics and Child Health</i> , 2019, 24, 333-335.	0.6	18
42	Development of mini-SSPedi for children 4-7 years of age receiving cancer treatments. <i>BMC Cancer</i> , 2019, 19, 32.	2.6	27
43	Initial development of Supportive care Assessment, Prioritization and Recommendations for Kids (SPARK), a symptom screening and management application. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 9.	3.0	17
44	Symptom documentation and intervention provision for symptom control in children receiving cancer treatments. <i>European Journal of Cancer</i> , 2019, 109, 120-128.	2.8	23
45	Longitudinal evaluation of Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK), a symptom screening and management application. <i>BMC Cancer</i> , 2019, 19, 458.	2.6	13
46	Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1907-1915.	0.9	3
47	Reducing pain in children with cancer: Methodology for the development of a clinical practice guideline. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27698.	1.5	14
48	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
49	Measurement properties of instruments to assess pain in children and adolescents with cancer: a systematic review protocol. <i>Systematic Reviews</i> , 2019, 8, 33.	5.3	1
50	Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27646.	1.5	41
51	Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27456.	1.5	2
52	Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27584.	1.5	16
53	Severely bothersome fatigue in children and adolescents with cancer and hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2019, 27, 2665-2671.	2.2	17
54	Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 97-110.	2.4	11

#	ARTICLE	IF	CITATIONS
55	Taste changes in children with cancer and hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2019, 27, 2247-2254.	2.2	10
56	Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27471.	1.5	13
57	Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2019, 37, 19-19.	1.6	1
58	Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments. Journal of the National Cancer Institute, 2018, 110, 661-668.	6.3	68
59	Response to Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives™. British Journal of Clinical Pharmacology, 2018, 84, 604-604.	2.4	1
60	Validation of the Proxy Version of Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments. Journal of Pain and Symptom Management, 2018, 56, 107-112.	1.2	28
61	Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2018, 122, 52-59.	4.4	111
62	Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blind, randomized controlled trial. Cancer, 2018, 124, 1188-1196.	4.1	15
63	Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2018, 40, e278-e282.	0.6	7
64	Management of fatigue in children and adolescents with cancer and in paediatric recipients of haemopoietic stem-cell transplants: a clinical practice guideline. The Lancet Child and Adolescent Health, 2018, 2, 371-378.	5.6	44
65	Evaluation of the electronic self-report Symptom Screening in Pediatrics Tool (SSPedi). BMJ Supportive and Palliative Care, 2018, 8, 110-116.	1.6	41
66	Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Supportive Care in Cancer, 2018, 26, 549-555.	2.2	25
67	Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2018, 36, 3162-3171.	1.6	25
68	Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study. Pediatric Hematology and Oncology, 2018, 35, 288-296.	0.8	4
69	Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. Pediatric Blood and Cancer, 2018, 65, e27374.	1.5	19
70	Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Supportive and Palliative Care, 2017, 7, 7-16.	1.6	90
71	Parent Attributions About Child Symptoms Related to Cancer Therapy. Journal of Pediatric Oncology Nursing, 2017, 34, 44-50.	1.5	8
72	Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: A prospective, observational study. Pediatric Blood and Cancer, 2017, 64, e26603.	1.5	11

#	ARTICLE	IF	CITATIONS
73	Aprepitant and fosaprepitant drug interactions: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2148-2162.	2.4	62
74	Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26542.	1.5	88
75	Mind and body practices for fatigue reduction in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 210-216.	4.4	39
76	2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2017, 25, 317-321.	2.2	28
77	2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. <i>Supportive Care in Cancer</i> , 2017, 25, 323-331.	2.2	67
78	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2082-2094.	1.6	337
79	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	1.6	454
80	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017, 8, 90852-90867.	1.8	39
81	Strategies facilitating practice change in pediatric cancer: a systematic review. <i>International Journal for Quality in Health Care</i> , 2016, 28, 426-432.	1.8	3
82	Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 887-892.	1.5	16
83	Methodological issues identified during cognitive interviews in the development of a pediatric cancer symptom screening tool. <i>Psycho-Oncology</i> , 2016, 25, 349-353.	2.3	2
84	Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2054-2060.	1.6	45
85	Reply to "Pharmacokinetic and Analytical Issues in Busulfan Area Under the Curve Estimation and Simulation". <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 186.	2.0	0
86	Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1144-1151.	1.5	60
87	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1116-1125.	4.1	72
88	Chemotherapy-induced vomiting in children: some progress, more questions. <i>Lancet Oncology</i> , The, 2016, 17, 264-265.	10.7	2
89	The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2016, 39, 675-687.	3.2	45
90	The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2016, 39, 509-516.	3.2	13

#	ARTICLE	IF	CITATIONS
91	Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv357.	6.3	117
92	Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate. <i>Supportive Care in Cancer</i> , 2016, 24, 1365-1371.	2.2	14
93	Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 665-665.	1.4	0
94	A review of symptom screening tools in pediatric cancer patients. <i>Current Opinion in Oncology</i> , 2015, 27, 285-290.	2.4	19
95	Construct validity and reliability of a real-time multidimensional smartphone app to assess pain in children and adolescents with cancer. <i>Pain</i> , 2015, 156, 2607-2615.	4.2	85
96	Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multicenter review. <i>Pediatric Blood and Cancer</i> , 2015, 62, 496-501.	1.5	34
97	Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1471-1478.	2.0	39
98	Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review. <i>Paediatric Drugs</i> , 2015, 17, 315-321.	3.1	25
99	Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 393-400.	1.5	79
100	The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2014, 37, 791-804.	3.2	23
101	Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 185-196.	1.4	3
102	Initial development of the Symptom Screening in Pediatrics Tool (SSPedi). <i>Supportive Care in Cancer</i> , 2014, 22, 71-75.	2.2	52
103	Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1506-1512.	1.5	57
104	Methylnaltrexone for Opioid-Induced Constipation in Pediatric Oncology Patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1667-1670.	1.5	33
105	Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 418-423.	2.0	13
106	Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive care. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1027-1030.	1.5	36
107	Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1073-1082.	1.5	112
108	Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children. <i>Leukemia and Lymphoma</i> , 2013, 54, 105-109.	1.3	2

#	ARTICLE	IF	CITATIONS
109	Development and Testing of a Multidimensional iPhone Pain Assessment Application for Adolescents with Cancer. <i>Journal of Medical Internet Research</i> , 2013, 15, e51.	4.3	243
110	Fluoroquinolones in Children With Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 431-435.	2.0	16
111	A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 353-359.	2.0	15
112	A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. <i>Supportive Care in Cancer</i> , 2012, 20, 2295-2304.	2.2	21
113	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 4427-4438.	1.6	311
114	A systematic review of symptom assessment scales in children with cancer. <i>BMC Cancer</i> , 2012, 12, 430.	2.6	59
115	Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials. <i>Supportive Care in Cancer</i> , 2012, 20, 1135-1145.	2.2	46
116	A Reliable and Safe Method of Collecting Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations. <i>Pharmacotherapy</i> , 2011, 31, 776-784.	2.6	5
117	Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2011, 57, 191-198.	1.5	78
118	Symptom assessment in children receiving cancer therapy: the parents' perspective. <i>Supportive Care in Cancer</i> , 2010, 18, 281-299.	2.2	75
119	Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. <i>Supportive Care in Cancer</i> , 2010, 18, 913-919.	2.2	36
120	Once-Daily Gentamicin Dosing in Children with Febrile Neutropenia Resulting from Antineoplastic Therapy. <i>Pharmacotherapy</i> , 2010, 30, 43-51.	2.6	13
121	Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 1749-1753.	2.4	2
122	Cyclosporine Dose Intensity and Risk of Acute Graft-versus-Host Disease: Trough versus Area under the Curve. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 866-867.	2.0	1
123	Optimizing Emetic Control in Children Receiving Antineoplastic Therapy. <i>Paediatric Drugs</i> , 2010, 12, 51-61.	3.1	26
124	Cyclosporine-Induced Pain Syndrome in a Child Undergoing Hematopoietic Stem Cell Transplant. <i>Annals of Pharmacotherapy</i> , 2009, 43, 767-771.	1.9	20
125	Stability of an extemporaneous oral liquid aprepitant formulation. <i>Supportive Care in Cancer</i> , 2009, 17, 701-706.	2.2	23
126	Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2009, 52, 14-19.	1.5	34



#	ARTICLE	IF	CITATIONS
127	Daclizumab therapy for children with corticosteroid-resistant acute graft-versus-host disease. <i>Pediatric Transplantation</i> , 2009, 13, 332-337.	1.0	6
128	Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1064-1068.	2.0	53
129	Sevelamer hydrochloride: A novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. <i>Pediatric Blood and Cancer</i> , 2008, 51, 59-61.	1.5	17
130	Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. <i>Bone Marrow Transplantation</i> , 2008, 42, 455-459.	2.4	4
131	IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 576-582.	2.0	22
132	Documentation of Pediatric Drug Safety in Manufacturers' Product Monographs. <i>Paediatric Drugs</i> , 2008, 10, 193-197.	3.1	6
133	Determination of Area Under the Whole Blood Concentration versus Time Curve after First Intravenous Cyclosporine Dose in Children Undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 434-438.	2.0	12
134	Achievement of Target Cyclosporine Concentrations as a Predictor of Severe Acute Graft Versus Host Disease in Children Undergoing Hematopoietic Stem Cell Transplantation and Receiving Cyclosporine and Methotrexate Prophylaxis. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 750-757.	2.0	22
135	EFFICACY AND SAFETY OF CASPOFUNGIN FOR THE EMPIRIC MANAGEMENT OF FEVER IN NEUTROPENIC CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 854-856.	2.0	19
136	Pharmacokinetic Disposition and Clinical Outcomes in Infants and Children Receiving Intravenous Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 307-314.	2.0	56
137	Defibrotide for the treatment of hepatic veno-occlusive disease in children. <i>Pediatric Blood and Cancer</i> , 2007, 48, 700-704.	1.5	64
138	Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2007, 140, 071119224223001-???	2.5	29
139	A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. <i>Supportive Care in Cancer</i> , 2006, 14, 268-276.	2.2	31
140	Disposition of Two Oral Formulations of Cyclosporine in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants. <i>Pharmacotherapy</i> , 2006, 26, 15-22.	2.6	8
141	Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents. <i>Pharmacotherapy</i> , 2006, 26, 1221-1231.	2.6	96
142	Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 5207-5215.	1.6	119
143	Medication Safety: Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing. <i>Annals of Pharmacotherapy</i> , 2006, 40, 805-811.	1.9	18
144	Extent of Agreement in Gentamicin Concentration Between Serum That Is Drawn Peripherally and From Central Venous Catheters. <i>Pediatrics</i> , 2006, 118, e1650-e1656.	2.1	19

#	ARTICLE	IF	CITATIONS
145	Determination of a Limited Sampling Strategy for IV Busulfan Dose Individualization in Children.. Blood, 2006, 108, 2942-2942.	1.4	15
146	Appropriate busulfan dosing. Bone Marrow Transplantation, 2005, 35, 199-200.	2.4	1
147	Pediatric Pharmacotherapeutic Education: Current Status and Recommendations to Fill the Growing Need. Pharmacotherapy, 2005, 25, 1277-1282.	2.6	35
148	Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once-Daily versus Thrice-Daily Administration. Pharmacotherapy, 2004, 24, 564-573.	2.6	11
149	Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. Pediatric Blood and Cancer, 2004, 42, 598-603.	1.5	32
150	Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients. Journal of Clinical Oncology, 2004, 22, 1222-1227.	1.6	55
151	Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children. Paediatric Drugs, 2003, 5, 597-613.	3.1	35
152	Randomized Controlled Trial of Once- Versus Thrice-Daily Tobramycin in Febrile Neutropenic Children Undergoing Stem Cell Transplantation. Journal of the National Cancer Institute, 2003, 95, 1869-1877.	6.3	31
153	Therapeutic Drug Monitoring of Lamotrigine. Annals of Pharmacotherapy, 2002, 36, 917-920.	1.9	29
154	Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplantation, 2002, 30, 119-124.	2.4	14
155	Delayed nausea and vomiting in children receiving antineoplastics. Medical and Pediatric Oncology, 2001, 37, 115-121.	1.0	18
156	Oral syringe for extemporaneously preparing doses. American Journal of Health-System Pharmacy, 1998, 55, 735-735.	1.0	3
157	Stability of propafenone hydrochloride in i.v. solutions. American Journal of Health-System Pharmacy, 1997, 54, 1293-1295.	1.0	4
158	Pharmacist intervention in prescribing of cefuroxime for pediatric patients. American Journal of Health-System Pharmacy, 1990, 47, 1350-1353.	1.0	4
159	Comparative Evaluation of Benzylamine Oral Rinse in Children with Antineoplastic-Induced Stomatitis. Drug Intelligence & Clinical Pharmacy, 1987, 21, 359-361.	0.4	23
160	Creating and adapting an infection management care pathway in pediatric oncology. Supportive Care in Cancer, 0, , .	2.2	4